Event Details
Circa 2015
Description
Trading of Regeneron shares was halted pending news.
Participants (1)
| Name | Type | Mentions | |
|---|---|---|---|
| Regeneron | organization | 22 | View Entity |
Source Documents (1)
HOUSE_OVERSIGHT_026364.jpg
This article discusses the new cholesterol drug, Praluent, from Regeneron and Sanofi, focusing on its high price, which is 46% higher than analyst forecasts. It details the FDA's approval for a broader patient group than expected, the potential for wide prescription by doctors despite the label, and the expected resistance from insurance companies who will likely restrict its use. The article also includes commentary from executives at Regeneron and Sanofi, as well as analysts and cardiologists, on the drug's market potential and place alongside existing treatments like statins.
Related Events
Events with shared participants
Investor Relations Conference Call hosted by Sanofi and Regeneron to discuss Praluent.
2015-07-24 • Teleconference / Webcast
Investor Relations Conference Call on Praluent for the financial community.
2015-07-24 • Teleconference / Webcast
The FDA clearing the drug Praluent for patients with heterozygous familial hypercholesterolemia and certain types of heart disease.
Date unknown
ODYSSEY clinical trial program.
2025-12-01
Investor Relations Conference Call on Praluent hosted by Sanofi and Regeneron
2015-07-24 • Conference Call / Webcast
Expected final decision by European Commission on Marketing Authorization Application
2015-09-01 • European Union
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein event